| [1] |
Pang Y, Yuan H, Ren A, et al. Primary malignant melanoma of the female genital tract synchronously involving the vulva and uterine cervix: A case report[J]. Medicine(Baltimore), 2019, 98(30):e16366. doi: 10.1097/MD.0000000000016366.
doi: 10.1097/MD.0000000000016366
|
| [2] |
郭琦, 熊超逸, 叶璐. 原发性子宫颈恶性黑色素瘤6例临床病理分析[J]. 临床与实验病理学杂志, 2021, 37(11):1383-1385. doi: 10.13315/j.cnki.cjcep.2021.11.026.
doi: 10.13315/j.cnki.cjcep.2021.11.026
|
| [3] |
Yin C, Yang A, Zhang Y, et al. Primary Cervical Malignant Melanoma: 2 Cases and a Literature Review[J]. Int J Gynecol Pathol, 2019, 38(2):196-203. doi: 10.1097/PGP.0000000000000480.
doi: 10.1097/PGP.0000000000000480
pmid: 29474317
|
| [4] |
Lea JS, Lin KY. Cervical cancer[J]. Obstet Gynecol Clin North Am, 2012, 39(2):233-253. doi: 10.1016/j.ogc.2012.02.008.
doi: 10.1016/j.ogc.2012.02.008
|
| [5] |
沈小静, 于静, 贺其志, 等. 原发性女性生殖系统恶性黑色素瘤临床病理特点[J]. 中国妇产科临床杂志, 2020, 21(3):254-257. doi: 10.13390/j.issn.1672-1861.2020.03.011.
doi: 10.13390/j.issn.1672-1861.2020.03.011
|
| [6] |
Yuan G, Wu L, Li B, et al. Primary malignant melanoma of the cervix: Report of 14 cases and review of literature[J]. Oncotarget, 2017, 8(42):73162-73167. doi: 10.18632/oncotarget.17183.
doi: 10.18632/oncotarget.17183
pmid: 29069859
|
| [7] |
Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects[J]. Oncologist, 2011, 16(1):5-24. doi: 10.1634/theoncologist.2010-0190.
doi: 10.1634/theoncologist.2010-0190
pmid: 21212434
|
| [8] |
Bajetta E, Del Vecchio M, Nova P, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma[J]. Ann Oncol, 2006, 17(4):571-577. doi: 10.1093/annonc/mdl007.
doi: 10.1093/annonc/mdl007
pmid: 16469753
|
| [9] |
Sugiyama VE, Chan JK, Kapp DS. Management of melanomas of the female genital tract[J]. Curr Opin Oncol, 2008, 20(5):565-569. doi: 10.1097/CCO.0b013e32830b0dda.
doi: 10.1097/CCO.0b013e32830b0dda
pmid: 19106662
|
| [10] |
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma[J]. N Engl J Med, 2019, 381(16):1535-1546. doi: 10.1056/NEJMoa1910836.
doi: 10.1056/NEJMoa1910836
|
| [11] |
Mignard C, Deschamps Huvier A, Gillibert A, et al. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma[J]. J Oncol, 2018, 2018:1908065. doi: 10.1155/2018/1908065.
doi: 10.1155/2018/1908065
|
| [12] |
D′Angelo SP, Larkin J, Sosman JA, et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis[J]. J Clin Oncol, 2017, 35(2):226-235. doi: 10.1200/JCO.2016.67.9258.
doi: 10.1200/JCO.2016.67.9258
pmid: 28056206
|
| [13] |
Li S, Wu X, Yan X, et al. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis[J]. J Immunother Cancer, 2022, 10(2):e004036. doi: 10.1136/jitc-2021-004036.
doi: 10.1136/jitc-2021-004036
|
| [14] |
Pusceddu S, Bajetta E, Carcangiu ML, et al. A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer[J]. Crit Rev Oncol Hematol, 2012, 81(2):185-195. doi: 10.1016/j.critrevonc.2011.03.008.
doi: 10.1016/j.critrevonc.2011.03.008
pmid: 21515070
|
| [15] |
Sun H, Chen Y, Chen Y, et al. Primary malignant melanoma of the cervix: 14 cases and literature overview[J]. Melanoma Res, 2018, 28(6):578-585. doi: 10.1097/CMR.0000000000000469.
doi: 10.1097/CMR.0000000000000469
pmid: 30044323
|